PD35-08 ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBASE TRIAL

You have accessJournal of UrologyProstate Cancer: Detection & Screening VI (PD35)1 Apr 2019PD35-08 ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBASE TRIAL Kathleen Herkommer*, Valentin Henri Meissner, Zübeyde Ertilav, Martina Kron, Helga Schulwitz, Peter Albers, Christian Arsov, Markus Kuczyk, Florian Imkamp, Markus Hohenfellner, Boris Hadaschik, and Jürgen Erich Gschwend Kathleen Herkommer*Kathleen Herkommer* More articles by this author , Valentin Henri MeissnerValentin Henri Meissner More articles by this author , Zübeyde ErtilavZübeyde Ertilav More articles by this author , Martina KronMartina Kron More articles by this author , Helga SchulwitzHelga Schulwitz More articles by this author , Peter AlbersPeter Albers More articles by this author , Christian ArsovChristian Arsov More articles by this author , Markus KuczykMarkus Kuczyk More articles by this author , Florian ImkampFlorian Imkamp More articles by this author , Markus HohenfellnerMarkus Hohenfellner More articles by this author , Boris HadaschikBoris Hadaschik More articles by this author , and Jürgen Erich GschwendJürgen Erich Gschwend More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000556340.70570.d4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Previous studies showed that, besides diseases of the prostate, the intake of certain medication may influence the PSA level. In this study, we investigated the effect of common medication on the PSA level in more than 13,000 men. Furthermore, we aimed to assess the effect of low dose finasteride (1 mg) on PSA, as the use of 5 mg finasteride is known to affect PSA levels. METHODS: We included 45-year-old men of the PROBASE trial between April 2014 and April 2017. A short anamnesis with documentation of current medication was conducted by a study physician. Most commonly prescribed medication was classified into metabolic (metformin, insulin, statins), cardiovascular (beta-blocker, thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers), and central nervous system agents. In a separate analysis, we investigated PSA levels of men receiving low dose finasteride therapy of 1 mg. PSA levels of each subgroup were compared with the PSA levels of the remaining sample (men without medication/comorbidities) via Wilcoxon test. RESULTS: PSA levels of 13,021 subjects were analyzed. Median PSA level was 0.7 ng/ml (IQR: 0.5-1.1). Use of metabolic and cardiovascular agents, metformin, insulin, and ACE inhibitors were associated with 20%, 14%, and 7% (all p<0.01) lower PSA levels, respectively. Use of central nervous system agents was not associated with a change in PSA level. Low dose finasteride therapy (1 mg) was associated with a median decrease in PSA level of 31% (p<0.001). CONCLUSIONS: Our study shows that the intake of metformin, insulin, and ACE inhibitors is associated with a lower PSA level. Use of statins, in contrast to previous studies, did not result in a decrease in PSA concentrations whereas low dose finasteride therapy (1 mg) for male androgenetic alopecia was associated with a lower PSA level. Therefore, we suggest applying the same recommendations for interpretation of a PSA test in men receiving 1 mg/day finasteride, as we do for men receiving 5 mg/day finasteride. Source of Funding: none Munich, Germany; Ulm, Germany; Munich, Germany; Dusseldorf, Germany; Hannover, Germany; Heidelberg, Germany; Munich, Germany© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e652-e652 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kathleen Herkommer* More articles by this author Valentin Henri Meissner More articles by this author Zübeyde Ertilav More articles by this author Martina Kron More articles by this author Helga Schulwitz More articles by this author Peter Albers More articles by this author Christian Arsov More articles by this author Markus Kuczyk More articles by this author Florian Imkamp More articles by this author Markus Hohenfellner More articles by this author Boris Hadaschik More articles by this author Jürgen Erich Gschwend More articles by this author Expand All Advertisement PDF downloadLoading ...